Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07EEN
|
|||
| Former ID |
DCL000870
|
|||
| Drug Name |
Lixivaptan
|
|||
| Synonyms |
168079-32-1; VPA-985; WAY-VPA-985; UNII-8F5X4B082E; VPA985; CHEMBL49429; CRTX-080; VPA 985; 8F5X4B082E; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; Lixar; Lixivaptan [USAN:INN]; Lixivaptan (USAN/INN); WAY VPA-985; Lixivaptan (VPA-985); AC1L59LM; WAY-VPA 985; GTPL2238; SCHEMBL1649340; DTXSID00168472; PPHTXRNHTVLQED-UHFFFAOYSA-N; ZINC600399; EX-A1129; BCP09167; BDBM50065115; AKOS022181388; AN-1842; CS-7512; API0009250; NCGC00485402-01; VPA985; BF-Derm1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyponatraemia [ICD-11: 5C72; ICD-10: E87; ICD-9: 276.1] | Phase 3 | [1], [2] | |
| Congestive heart failure [ICD-11: BD10; ICD-10: I50.0; ICD-9: 428] | Phase 2 | [1], [2] | ||
| Skin infection [ICD-11: 1F28-1G0Z; ICD-10: L00-L99; ICD-9: 680-709] | Phase 2 | [3] | ||
| Company |
Wyeth-Ayerst; Cardiokine
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H21ClFN3O2
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
|
|||
| InChI |
1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
|
|||
| InChIKey |
PPHTXRNHTVLQED-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 168079-32-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980888, 10257813, 14883146, 33497450, 47206571, 51007980, 57352187, 85210111, 103230841, 103960062, 113473195, 125299293, 128948849, 134338769, 134339327, 134340482, 135127191, 135650528, 137263757, 137267623, 141986343, 164228268, 164761614, 176225592, 179150049, 198968309, 202821333, 215780791, 223532830, 223661309, 224998594, 227838647, 251971379
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histidine decarboxylase (HDC) | Target Info | Inhibitor | [4] |
| Vasopressin V2 receptor (V2R) | Target Info | Antagonist | [5] | |
| KEGG Pathway | Histidine metabolism | |||
| Metabolic pathways | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vasopressin-regulated water reabsorption | ||||
| Panther Pathway | Histamine synthesis | |||
| CCKR signaling map ST | ||||
| Pathwhiz Pathway | Histidine Metabolism | |||
| Vasopressin Regulation of Water Homeostasis | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Reactome | Vasopressin-like receptors | |||
| G alpha (s) signalling events | ||||
| Vasopressin regulates renal water homeostasis via Aquaporins | ||||
| WikiPathways | Biogenic Amine Synthesis | |||
| Metabolism of amino acids and derivatives | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Regulation of Water Balance by Renal Aquaporins | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2238). | |||
| REF 2 | Physical state of kappa-carrageenan modulates the mode of action of kappa-carrageenase from Pseudoalteromonas carrageenovora. Biochem J. 2009 May 1;419(3):545-53. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020550) | |||
| REF 4 | Clinical pipeline report, company report or official report of Biofrontera (2009). | |||
| REF 5 | Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.